SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Higuchi Ichiyō — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientHiguchi Ichiyō
Date of birth1872-05-02
IdentifiersMRN HR-NI029-SYN-TD; SSN (made up) 000-29-5108
Document date1896-04-17
AuthorAiko Lindgren-Tanaka, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Results visit: sputum tests, with infectious diseases consultation the same day. [S]

History of Present Illness

Ms. Higuchi returns three days after her first visit for her results and is seen by Dr. Abernathy-Okoye of infectious diseases today. She brought the second and third sputum specimens, the last collected on waking this morning. Since her first visit she has stayed home, slept in her own room with the window open, and worn a surgical mask in the shared rooms; no one has visited. The cough is unchanged, with a little white sputum and no blood, and she still has evening fevers and night sweats. She is eating a little more since the dietitian's first call. She has not written since her first visit. She is worried about the people she lives with and about the cost of treatment. [S]

ElementDetail
SymptomsCough, evening fevers and night sweats unchanged; no hemoptysis
PrecautionsAt home with a mask in shared rooms; no visitors
TestingThree sputum specimens complete; blood results back

Review of Systems

SystemResultFinding
RespiratoryPositiveCough with a little white sputum; no blood; breathless on the stairs
ConstitutionalPositiveEvening fevers, night sweats and tiredness
EyesNegativeNo blurred vision
PsychiatricPositiveWorried about her household and costs; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 100 mg tablets, two tablets (200 mg) daily200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route1896-04-17 to 1896-10-15completedS
Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route1896-04-17 to 1896-10-15completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phaseOral route1896-04-17 to 1896-06-11completedS
Ethambutol 100 mg tablets, six tablets (600 mg) daily600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results returnOral route1896-04-17 to 1896-05-22stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route1896-04-17 to 1896-10-15completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1896-04-17Body height148cmS
1896-04-17Body weight38.4kgS
1896-04-17Body mass index (BMI) [Ratio]17.5kg/m2S
1896-04-17Systolic blood pressure96mm[Hg]S
1896-04-17Diastolic blood pressure60mm[Hg]S
1896-04-17Heart rate100/minS
1896-04-17Respiratory rate20/minS
1896-04-17Body temperature37.6CelS
1896-04-17Oxygen saturation in Arterial blood by Pulse oximetry96%S

Physical Exam

Vital signs recorded on 1896-04-17; see the Vital Signs section. [S]

SystemFinding
GeneralThin and tired; weight 38.4 kg; temperature 37.6 °C, pulse 100; seen in an airborne infection isolation room with staff wearing respirators
RespiratoryFine crackles over the right upper zone; no wheeze
EyesNo icterus
AbdomenSoft and non-tender; liver not enlarged

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and cultureresolvedconfirmed R05.3S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D).
Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected)activeconfirmed A15.0S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic.
Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dLactiveconfirmed E44.0S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty.
Low and irregular income from writing, with a household to support; costs of care are a barrieractiveconfirmed Z59.6S — Synthetic social need anchored to her documented poverty and household responsibilities.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratorySputum smear and cultureAt diagnosis, at two weeks, and at the end of the intensive phase (two months)Completed todayThree specimens, one on waking: smears negative for acid-fast bacilli; liquid and solid cultures pending
LaboratoryXpert MTB/RIF Ultra (nucleic acid amplification with rifampin resistance)At diagnosisCompleted todayMycobacterium tuberculosis detected, low; rifampin resistance not detected
LaboratoryDrug susceptibility testing of the first isolateOnce, on the first positive cultureOrderedPhenotypic susceptibility to first-line drugs to be set up on the first positive culture
LaboratoryHIV testAt diagnosisUp to dateHIV-1/2 antigen and antibody test negative
LaboratoryHepatitis B and C serologyAt diagnosisUp to dateHepatitis B surface antigen, surface antibody and core antibody negative (not immune); hepatitis C antibody negative
LaboratoryPregnancy testBefore starting treatment in a woman who could be pregnantUp to dateNegative at intake
LaboratoryDiabetes screen (hemoglobin A1c)At diagnosisUp to date5.1% at intake
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptomsUp to dateNormal at intake (ALT 12, AST 19 U/L, bilirubin 0.4 mg/dL); albumin 3.3 g/dL
ImagingVisual acuity and color visionBaseline and monthly while on ethambutolUp to date85 letters in each eye with normal color vision at intake, before ethambutol
ImagingChest X-rayAt diagnosis and at the end of treatment as a new baselineUp to dateRight upper lobe opacities without a cavity at intake
Medication safetyRegimen choice and weight-based dosesAt the start of treatmentCompleted todayStandard six-month regimen; not eligible for the four-month rifapentine-moxifloxacin regimen at 38.5 kg. Isoniazid 5, rifampin 12, pyrazinamide 26 and ethambutol 16 mg/kg
Medication safetyDoses observed and missed (video-observed therapy)Every visitCompleted todayFirst dose observed in the clinic; video-observed therapy from tomorrow
Medication safetyRifampin drug-interaction review, including hormonal contraceptionWith every new medicineCompleted todayNo other medicines; told that rifampin weakens hormonal contraceptives and interacts with many drugs
Self-managementHome precautions and the criteria for releaseUntil two weeks of treatment with clinical improvement, for smear-negative diseaseCompleted todayPrecautions at home continue; smear-negative, so treated as an outpatient
ReferralNotification to the public health center (Infectious Diseases Control Law, Article 12)At once on diagnosisCompleted todayNotified today; the center was told of the suspected case at intake
ReferralContact investigation (household and close contacts)Led by the public health center, from diagnosisReferredThe public health center will assess her household and close contacts; their results belong to their own records
ReferralPublic funding and other help with costsAt diagnosisCompleted todayPublic funding application completed with the social worker
Self-managementWeight and nutritionEvery visit; dose review if weight changes by more than about 5 kgCompleted today38.4 kg; dietitian and supplement drinks
SurveyDepression screen (PHQ-9)At diagnosis, at two months, and at the end of treatmentUp to datePHQ-9 8 at intake, item 9 scored 0
ReferralInfectious diseases consultationOnce at diagnosis, then as advisedCompleted todaySeen today by Dr. Abernathy-Okoye

Goal progress:

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025); WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022); Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current); 結核医療費の公費負担 (Public funding of tuberculosis medical costs under Articles 37 and 37-2 of the Infectious Diseases Control Law) (current); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012)

Follow-up: Two-week review with liver tests, vision and a sputum specimen. Call the same day for hepatitis symptoms or any change in vision. Next scheduled visit 1896-05-01: two-week review on treatment: culture result, liver tests, vision, and release from precautions. [S]